Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Acrivon Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/23/2023 4 Blume-Jensen Peter (President and CEO) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Granted 493,994 shares @ $0
06/28/2023 4 BAUM CHARLES M (Director) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Granted 32,500 options to buy @ $12.88, valued at $418.6k
06/28/2023 4 Chione Ltd (10% Owner) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Sold 16 shares @ $12.93, valued at $206.9
06/06/2023 4 Devroe Eric (COO) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Exercised 9,225 options to buy @ $1.04, valued at $9.6k
06/01/2023 4 Blume-Jensen Peter (President and CEO) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Exercised 33,605 options to buy @ $3.88, valued at $130.4k
11/21/2022 4 Chione Ltd (10% Owner) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Bought 400,000 shares @ $12.5, valued at $5M
Converted 3,445,940 shares @ $0
Converted 10,657 shares @ $0
Converted 8,497,692 preferred shares @ $0
Converted 26,281 preferred shares @ $0
11/21/2022 4 RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Converted 994,706 shares @ $0
Bought 3,389,500 shares @ $12.5, valued at $42.4M
Converted 426,302 shares @ $0
Converted 2,452,947 preferred shares @ $0
Converted 1,051,263 preferred shares @ $0
11/21/2022 4 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. (10% Owner) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Converted 888,130 shares @ $0
Converted 2,190,131 preferred shares @ $0
11/16/2022 4 DiRocco Derek (Director) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Granted 35,235 options to buy @ $12.5, valued at $440.4k
11/16/2022 4 RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Granted 35,235 options to buy @ $12.5, valued at $440.4k
11/16/2022 4 Shacham Sharon (Director) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Granted 35,235 options to buy @ $12.5, valued at $440.4k
11/16/2022 4 TOMSICEK MICHAEL JOHN (Director) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Granted 35,235 options to buy @ $12.5, valued at $440.4k
11/16/2022 4 Gamelin Erick (Chief Medical Officer) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Granted 20,030 shares @ $0
Granted 60,090 options to buy @ $12.5, valued at $751.1k
11/16/2022 4 Devroe Eric (COO) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Granted 33,383 shares @ $0
Granted 100,150 options to buy @ $12.5, valued at $1.3M
11/16/2022 4 Holm-Jorgensen Rasmus (CFO) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Granted 20,030 shares @ $0
Granted 60,090 options to buy @ $12.5, valued at $751.1k
11/16/2022 4 Masson Kristina (EVP - Business Operations) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Granted 26,707 shares @ $0
Granted 934,731 shares @ $0
Granted 503,419 shares @ $0
Granted 60,090 shares @ $0
Granted 80,120 options to buy @ $12.5, valued at $1M
Granted 180,269 options to buy @ $12.5, valued at $2.3M
11/16/2022 4 Blume-Jensen Peter (President and CEO) has filed a Form 4 on Acrivon Therapeutics, Inc.
Txns: Granted 934,731 shares @ $0
Granted 503,419 shares @ $0
Granted 60,090 shares @ $0
Granted 26,707 shares @ $0
Granted 180,269 options to buy @ $12.5, valued at $2.3M
Granted 80,120 options to buy @ $12.5, valued at $1M

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy